COST PER RESPONDER ANALYSIS OF GUSELKUMAB VERSUS ETANERCEPT USING EFFICACY RESULTS FROM PIVOTAL CLINICAL TRIALS IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

被引：0

作者：

Teeple, A. ^{[1
]}

Muser, E. ^{[1
]}

机构：

[1] Janssen Sci Affairs LLC, Horsham, PA USA

来源：

VALUE IN HEALTH | 2018年 / 21卷

关键词：

D O I：

10.1016/j.jval.2018.04.1635

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PSS14

引用

页码：S241 / S241

页数：1

共 50 条

[1] Cost-per-responder analysis of guselkumab versus ixekizumab with the use of efficacy results from pivotal clinical trials in patients with moderate to severe plaque psoriasis
Teeple, Amanda
Muser, Erik
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB88 - AB88
[2] Cost per responder of apremilast and etanercept in patients with moderate to severe plaque psoriasis using results from LIBERATE
Tencer, Tom
Clancy, Zoe
Zhang, Frank
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB242 - AB242
[3] Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis
Martin, Silas
Feldman, Steven R.
Augustin, Matthias
Szapary, Philippe
Schenkel, Brad
JOURNAL OF DERMATOLOGICAL TREATMENT, 2011, 22 (03) : 138 - 143
[4] COST PER RESPONDER OF USTEKINUMAB VERSUS ETANERCEPT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: ANALYSIS FROM THE ACCEPT TRIAL
Feldman, S. R.
Augustin, M.
Martin, S.
Szapary, P.
Schenkel, B.
VALUE IN HEALTH, 2010, 13 (03) : A147 - A147
[5] Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany
Augustin, Matthias
Wirth, Daniel
Mahlich, Joerg
Pepper, Alicia N.
Druchok, Cheryl
JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 976 - 982
[6] COST PER RESPONDER ANALYSIS OF GUSELKUMAB VERSUS SECUKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS BASED ON THE ECLIPSE TRIAL
Druchok, C.
Pepper, A. N.
Garside, J.
Hassan, F.
VALUE IN HEALTH, 2019, 22 : S903 - S903
[7] Cost per responder of apremilast versus etanercept, adalimumab, and ustekinumab in patients with moderate to severe psoriasis
Feldman, Steven R.
Tencer, Tom
Clancy, Zoe
Zhang, Frank
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB229 - AB229
[8] Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis*
Teeple, Amanda
Fitzgerald, Timothy
JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (01) : 518 - 524
[9] Cost per responder for methotrexate versus other therapies in patients with moderate-to-severe plaque psoriasis in Italy
Pompilio, Giuseppe
Integlia, Davide
GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2022, 9 : 138 - 145
[10] Cost per responder with adalimumab versus ustekinumab treatment for moderate to severe psoriasis with suboptimal response to etanercept
Augustin, Matthias
Sundaram, Murali
Mulani, Parvez M.
Bao, Yanjun
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB189 - AB189

← 1 2 3 4 5 →